Vermont members faced particularly limited alternatives, as the state smaller healthcare market meant fewer providers offering cash-pay or compounded options compared to larger metropolitan areas
doi: 10.1038/s41598-017-18259-0 77 DobbinsRByerlyRGaddyRGaoFMaharKNapolitanoAet al
Jennifer Miller is a pediatric endocrinologist at the University of Florida, where she led trials that supported this drugs approval
Can GLP-1 medications be used in type 1 diabetes
an affiliate of Bausch Health US: Grant/Research Support, Jasmohan Bajaj: Bausch: Grant/Research Support, Sequana: Grant/Research Support, Cosmo: Grant/Research Support, Grifols: Grant/Research Support, Craig McClain: Novo Nordisk: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, Altimmune: Grant/Research Support, Target Pharma Solutions: Grant/Research Support, NIH: Grant/Research Support, VAMC: Grant/Research Support, Ayse Aytaman: Nothing to Disclose, Tamar Taddei: Nothing to Disclose 2138 COMPARATIVE ANALYSIS ON THE HEALTHCARE DISPARITIES AND IN-PATIENT MORTALITY OF HEPATORENAL SYNDROME AMONG DIFFERENT LIVER CIRRHOSIS ETIOLOGIES: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE 2020 DATABASE Raghav Bassi 1 Zubair Bodla 2 Mohammad AbuAssi 2 Harsimran Kalsi 2 Kobina Essilfie-Quaye 2 Yaseen Perbtani 2 Tony Brar 2 , 1 University of Central Florida College of Medicine, 2 University of Central Florida Background: The three most common causes of cirrhosis in the developed world are alcoholic liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatitis C virus (HCV)
has acted as consultant, advisory board member and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, an advisory board member Lexicon, Pfizer, ShouTi Pharma Inc, AstraZeneca and Medtronic and as a speaker for AstraZeneca, Napp Pharmaceuticals, Novartis and Amgen
